News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
232,759 Results
Type
Article (5177)
Company Profile (24)
Press Release (227558)
Multimedia
Podcasts (2)
Webinars (4)
Section
Business (82340)
Career Advice (463)
Deals (15072)
Drug Delivery (8)
Drug Development (19182)
Employer Resources (30)
FDA (3714)
Job Trends (3924)
News (120423)
Policy (7537)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (300)
Accelerated approval (6)
Adcomms (4)
Allergies (14)
Alliances (14823)
ALS (38)
Alzheimer's disease (296)
Antibody-drug conjugate (ADC) (40)
Approvals (3814)
Artificial intelligence (81)
Autoimmune disease (27)
Automation (5)
Bankruptcy (97)
Best Places to Work (2879)
Biosimilars (32)
Biotechnology (23)
Bladder cancer (34)
Brain cancer (7)
Breast cancer (101)
Cancer (888)
Cardiovascular disease (61)
Career advice (395)
Career pathing (3)
CAR-T (64)
CDC (2)
Cell therapy (168)
Cervical cancer (5)
Clinical research (16781)
Collaboration (354)
Compensation (373)
Complete response letters (8)
COVID-19 (311)
CRISPR (13)
C-suite (343)
Cystic fibrosis (28)
Data (1337)
Denatured (1)
Depression (21)
Diabetes (79)
Diagnostics (2114)
Digital health (7)
Diversity (1)
Diversity, equity & inclusion (13)
Drug discovery (31)
Drug pricing (14)
Drug shortages (2)
Duchenne muscular dystrophy (37)
Earnings (42773)
Editorial (5)
Employer branding (6)
Employer resources (32)
Events (39260)
Executive appointments (425)
FDA (4457)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (342)
Gene editing (24)
Generative AI (5)
Gene therapy (116)
GLP-1 (144)
Government (428)
Guidances (197)
Healthcare (5061)
HIV (10)
Huntington's disease (5)
IgA nephropathy (11)
Immunology and inflammation (39)
Immuno-oncology (7)
Indications (16)
Infectious disease (337)
Inflammatory bowel disease (36)
Inflation Reduction Act (3)
Influenza (6)
Intellectual property (32)
Interviews (53)
IPO (7895)
IRA (3)
Job creations (1124)
Job search strategy (361)
JPM (4)
Kidney cancer (10)
Labor market (10)
Layoffs (106)
Leadership (5)
Legal (2338)
Liver cancer (21)
Longevity (2)
Lung cancer (94)
Lymphoma (70)
Machine learning (3)
Management (10)
Manufacturing (140)
MASH (50)
Medical device (3944)
Medtech (3954)
Mergers & acquisitions (7582)
Metabolic disorders (217)
Multiple sclerosis (18)
NASH (6)
Neurodegenerative disease (54)
Neuropsychiatric disorders (12)
Neuroscience (542)
NextGen: Class of 2026 (1682)
Non-profit (732)
Now hiring (5)
Obesity (86)
Opinion (33)
Ovarian cancer (26)
Pain (26)
Pancreatic cancer (38)
Parkinson's disease (50)
Partnered (6)
Patents (56)
Patient recruitment (100)
Peanut (6)
People (25259)
Pharmaceutical (7)
Pharmacy benefit managers (2)
Phase 1 (5028)
Phase 2 (7288)
Phase 3 (5809)
Pipeline (1975)
Policy (17)
Postmarket research (625)
Preclinical (1961)
Press Release (66)
Prostate cancer (57)
Psychedelics (3)
Radiopharmaceuticals (109)
Rare diseases (180)
Real estate (1891)
Recruiting (8)
Regulatory (5562)
Reports (17)
Research institute (310)
Resumes & cover letters (69)
Rett syndrome (19)
RNA editing (1)
RSV (2)
Schizophrenia (49)
Series A (53)
Series B (55)
Sickle cell disease (10)
Special edition (1)
Spinal muscular atrophy (33)
Sponsored (5)
Startups (1022)
Stomach cancer (1)
Supply chain (13)
Tariffs (7)
The Weekly (1)
Vaccines (80)
Venture capital (9)
Weight loss (30)
Women's health (6)
Date
Today (29)
Last 7 days (148)
Last 30 days (542)
Last 365 days (8975)
2026 (813)
2025 (9099)
2024 (11073)
2023 (13245)
2022 (18772)
2021 (19729)
2020 (18300)
2019 (13247)
2018 (10250)
2017 (10038)
2016 (9189)
2015 (12159)
2014 (9605)
2013 (7740)
2012 (8352)
2011 (8810)
2010 (8650)
Location
Africa (186)
Alabama (19)
Alaska (2)
Arizona (74)
Arkansas (1)
Asia (11820)
Australia (1720)
California (3544)
Canada (1140)
China (169)
Colorado (145)
Connecticut (163)
Delaware (70)
Europe (25696)
Florida (542)
Georgia (67)
Idaho (24)
Illinois (161)
India (14)
Indiana (106)
Iowa (9)
Japan (166)
Kansas (36)
Kentucky (17)
Louisiana (8)
Maine (51)
Maryland (352)
Massachusetts (2811)
Michigan (104)
Minnesota (218)
Mississippi (1)
Missouri (32)
Montana (17)
Nebraska (12)
Nevada (46)
New Hampshire (17)
New Jersey (1024)
New Mexico (5)
New York (821)
North Carolina (480)
North Dakota (4)
Northern California (1854)
Ohio (116)
Oklahoma (5)
Oregon (6)
Pennsylvania (598)
Puerto Rico (1)
Rhode Island (19)
South America (280)
South Carolina (17)
Southern California (1306)
Tennessee (61)
Texas (486)
United States (12384)
Utah (111)
Virginia (84)
Washington D.C. (17)
Washington State (300)
West Virginia (2)
Wisconsin (57)
Wyoming (1)
232,759 Results for "cochlear corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Envoy Medical Secures New U.S. Patent for Innovative Cochlear Implant System Featuring a Removable Earplug Sensor and an Implanted Battery
Patent adds to Envoy Medical’s expanding intellectual property portfolio, reinforcing the Company’s leadership in next generation cochlear implant innovation
November 20, 2025
·
8 min read
Press Releases
Envoy Medical Reaches Enrollment Milestone in Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant
Enrollment momentum accelerates as Company advances toward full enrollment
December 18, 2025
·
7 min read
Press Releases
Envoy Medical Secures New Australian Patent for Cochlear Implant Innovation Aimed at Enhancing Input Signal-to-Noise Ratio
Patent strengthens Company’s global intellectual property portfolio and reinforces the Company’s commitment to establishing and protecting competitive advantages
December 16, 2025
·
9 min read
Press Releases
Envoy Medical to Host Fireside Chat with CEO Brent Lucas and the First Acclaim(R) Cochlear Implant Patient
Event to Take Place December 11th at 4:30 P.M. ET
December 4, 2025
·
6 min read
Press Releases
Envoy Medical Achieves Six-Month Milestone with First 10 Patients in Acclaim(R) Cochlear Implant Clinical Trial
November 18, 2025
·
1 min read
Press Releases
Envoy Medical Completes First Set of Activations in Final Stage of Pivotal Clinical Study for its First-Of-Its-Kind Fully Implanted Acclaim(R) Cochlear Implant
Momentum continues to build for Company as series of clinical milestones are met, design choices cement differentiation from competition, and timeline comes into focus
December 10, 2025
·
8 min read
Press Releases
Envoy Medical Announces First Three Patients Enrolled in Final Stage of Acclaim(R) Cochlear Implant Pivotal Clinical Trial
November 4, 2025
·
1 min read
Press Releases
Envoy Medical Marks Three-Year Anniversary of First Patient Receiving Its Breakthrough Fully Implanted Cochlear Implant
The Company looks to build on its recent momentum - receiving FDA approval to expand its pivotal clinical trial into the second and final stage
October 29, 2025
·
9 min read
Press Releases
Envoy Medical Expands Patent Portfolio by Securing Additional European Patent for Breakthrough Cochlear Implant Technology
Patent covers advanced signal processing for middle ear sensors, further advancing the Company’s position in leveraging the ear for fully implanted hearing devices
September 19, 2025
·
8 min read
Press Releases
Envoy Medical Successfully Reaches Three-Month Follow-Up Milestone in Clinical Trial of the Acclaim Fully Implanted Cochlear Implant
No Serious Adverse Events or Unanticipated Device Effects Reported; Company Confirms Program Remains On Track
September 3, 2025
·
9 min read
1 of 23,276
Next
